Company Overview and News

1
TPIC / TPI Composites, Inc. FORM 8-K (Current Report)

2018-07-09 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TPIC

1
TPI and Vestas Expand Relationship in Mexico

2018-07-09 globenewswire
SCOTTSDALE, Ariz., July 09, 2018 (GLOBE NEWSWIRE) -- TPI Composites, Inc., (TPI) (Nasdaq:TPIC), the only independent manufacturer of composite wind blades with a global footprint, announced today that Vestas Wind Systems A/S has exercised an option to add two more V136 blade manufacturing lines under an existing multiyear supply agreement. TPI will produce blades from six lines for Vestas at TPI’s new manufacturing hub in Matamoros, Mexico.
VWSYF TPIC VWDRY

28
7 Renewable Energy Stocks to Buy for Sunny Long-Term Returns | InvestorPlace

2018-06-27 investorplace
The 2020 Olympic Summer Games are to be held in Tokyo, Japan. The organizers of the games are planning to power the events with 100% renewable energy, which is great news for renewable energy stocks.
BAMGF NAV.PRD TAC TPIC NEE.PRI NAV NEE.PRJ RNW NEE.PRC NEE.PRQ REGI NEE.PRR EVA BAMKF NEE BAM TERP TRSWF BEP

2
TPIC / TPI Composites, Inc. FORM 8-K (Current Report)

2018-05-22 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TPIC

52
Merit Medical Systems price target raised to $62 from $55 at SunTrust Robinson Humphrey

2018-05-18 marketwatch
Growth at a reasonable price or the GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
TOWR MMSI IBTX INPAP TPIC DEST APVO EW INDB PDCO IBCP IP BSX SBAC

0
TPIC / TPI Composites, Inc. FORM 8-K (Current Report)

2018-05-17 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TPIC

0
TPIC / TPI Composites, Inc. FORM 8-K (Current Report)

2018-05-09 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TPIC

0
TPI and Vestas Expand Relationship in Mexico

2018-05-09 globenewswire
SCOTTSDALE, Ariz., May 09, 2018 (GLOBE NEWSWIRE) -- TPI Composites, Inc., (TPI) (Nasdaq:TPIC), the only independent manufacturer of composite wind blades with a global footprint, announced today that Vestas Wind Systems A/S has exercised an option for two additional blade manufacturing lines under an existing multiyear supply agreement. TPI will produce blades for Vestas’ 4 MW wind turbine platform at TPI’s new facility in Matamoros, Mexico.
VWSYF TPIC VWDRY

1
TPIC / TPI Composites, Inc. 8-K (Current Report)

2018-05-07 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TPIC

0
TPI and ENERCON Sign Long-Term Wind Blade Supply Agreement in Turkey

2018-05-07 globenewswire
SCOTTSDALE, Ariz., May 07, 2018 (GLOBE NEWSWIRE) -- TPI Composites, Inc., (TPI) (Nasdaq:TPIC), the only independent manufacturer of composite wind blades with a global manufacturing footprint, announced today that it has signed a multiyear supply agreement with ENERCON GmbH to provide blades from two manufacturing lines for the new EP3 platform turbines for wind markets including Europe and Turkey.
TPIC

0
TPIC / TPI Composites, Inc. 10-Q/A (Quarterly Report)

2018-05-07 sec.gov
tpic-10qa_20180331.htm
TPIC

0
TPI Composites 2018 Q1 - Results - Earnings Call Slides

2018-05-04 seekingalpha
The following slide deck was published by TPI Composites in conjunction with their 2018 Q1 earnings call.
TPIC

0
TPIC / TPI Composites, Inc. 10-Q (Quarterly Report)

2018-05-03 sec.gov
tpic-10q_20180331.htm
TPIC

0
TPIC / TPI Composites, Inc. FORM 8-K (Current Report)

2018-05-03 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TPIC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to TPIC / TPI Composites, Inc. on message board site Silicon Investor.

Netpicks
CUSIP: 87266J104